Bolsas y Mercados Españoles
Company
search
ORYZON GENOMICS, S.A.
AddressCARRERA DE SAN JERÓNIMO 15, 28014 MADRID 
Listed Capital2,653,144.55 Euros

 


ORYZON GENOMICS
ISINES0167733015 TickerORY Nominal0.05 MarketContinuous Market Admitted Capital2,653,144.55 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
01/07/2022Close2.38502.3900-0.212.38502.46002.32502.383739,35493,808.45
30/06/2022Close2.39002.4100-0.832.39002.41502.31002.362386,247203,742.45
X
01/07/2022 17:37:05
BidAsk
OrdersVolumePricePriceVolumeOrders
12,0002.35002.38508891
Data Delayed 15 minutes.

Last pay
TypeEx-datePayment DateConcept
 

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
30/06/202015 x 100Premium


 2022
until 30/06		2021202020192018
Capitalisation *
(thousands of euros)		126,820143,270185,720127,29684,702
Shares
(x 1,000)		53,06353,06353,06345,79039,123
Period Close Price
(euros)		2.39002.70003.50002.78002.1650
Period Last Price
(euros)		2.39002.70003.50002.78002.1650
Period High Price
(euros)		3.35004.39503.89504.46505.1800
Period Low Price
(euros)		2.03502.62501.47602.11502.0450
Volume
(thousands of shares)		16,61261,45491,82578,11395,258
Turnover
(thousands of euros)		45,621226,749285,561260,089336,854

Profile

Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.

For more information, visit www.oryzon.com
Source: Issuing company.
01/07/2022 00:01:00

Research

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.
Follow us in:
 GO
Copyright © BME 2022